Product References
A brain proteomic signature of incipient Alzheimer's disease in young APOE ε4 carriers identifies novel drug targets.
Science advances
Roberts JA,Varma VR,An Y,Varma S,Candia J,Fantoni G,Tiwari V,Anerillas C,Williamson A,Saito A,Loeffler T,Schilcher I,Moaddel R,Khadeer M,Lovett J,Tanaka T,Pletnikova O,Troncoso JC,Bennett DA,Albert MS,Yu K,Niu M,Haroutunian V,Zhang B,Peng J,Croteau DL,Resnick SM,Gorospe M,Bohr VA,Ferrucci L,Thambisetty M
MA1-19331 was used in Western Blot to characterize and validate the precise mechanisms mediating APOE ε4-associated risk of Alzheimer’s disease (AD), and show that drugs targeting three of these proteins—STAT3, YES1, and FYN—rescue distinct molecular phenotypes relevant to AD pathogenesis.
Fri Nov 12 00:00:00 UTC 2021
A brain proteomic signature of incipient Alzheimer's disease in young APOE ε4 carriers identifies novel drug targets.
Science advances
Roberts JA,Varma VR,An Y,Varma S,Candia J,Fantoni G,Tiwari V,Anerillas C,Williamson A,Saito A,Loeffler T,Schilcher I,Moaddel R,Khadeer M,Lovett J,Tanaka T,Pletnikova O,Troncoso JC,Bennett DA,Albert MS,Yu K,Niu M,Haroutunian V,Zhang B,Peng J,Croteau DL,Resnick SM,Gorospe M,Bohr VA,Ferrucci L,Thambisetty M
MA1-19331 was used in Western Blot to characterize and validate the precise mechanisms mediating APOE ε4-associated risk of Alzheimer’s disease (AD), and show that drugs targeting three of these proteins—STAT3, YES1, and FYN—rescue distinct molecular phenotypes relevant to AD pathogenesis.
Fri Nov 12 00:00:00 UTC 2021
A brain proteomic signature of incipient Alzheimer's disease in young APOE ε4 carriers identifies novel drug targets.
Science advances
Roberts JA,Varma VR,An Y,Varma S,Candia J,Fantoni G,Tiwari V,Anerillas C,Williamson A,Saito A,Loeffler T,Schilcher I,Moaddel R,Khadeer M,Lovett J,Tanaka T,Pletnikova O,Troncoso JC,Bennett DA,Albert MS,Yu K,Niu M,Haroutunian V,Zhang B,Peng J,Croteau DL,Resnick SM,Gorospe M,Bohr VA,Ferrucci L,Thambisetty M
MA1-19331 was used in Western Blot to characterize and validate the precise mechanisms mediating APOE ε4-associated risk of Alzheimer’s disease (AD), and show that drugs targeting three of these proteins—STAT3, YES1, and FYN—rescue distinct molecular phenotypes relevant to AD pathogenesis.
Fri Nov 12 00:00:00 UTC 2021
Human CEACAM1-LF regulates lipid storage in HepG2 cells via fatty acid transporter CD36.
The Journal of biological chemistry
Chean J,Chen CJ,Gugiu G,Wong P,Cha S,Li H,Nguyen T,Bhatticharya S,Shively JE
MA1-19331 was used in Western Blot to find that the fatty acid transporter CD36 was upregulated in the S508A mutant, coexpressed in BCs with CEACAM1, co-IPed with CEACAM1 and Src, and when downregulated via RNAi, an increase in lipid droplet content was observed.
Mon Nov 01 00:00:00 UTC 2021
Fyn-tau Ablation Modifies PTZ-Induced Seizures and Post-seizure Hallmarks of Early Epileptogenesis.
Frontiers in cellular neuroscience
Putra M,Puttachary S,Liu G,Lee G,Thippeswamy T
MA1-19331 was used in Western Blotting to demonstrate the role of Fyn and tau in seizures and their impact on the mediators of early epileptogenesis in PTZ model.
Sun Aug 04 00:00:00 UTC 2024
Oxidation of KCNB1 potassium channels triggers apoptotic integrin signaling in the brain.
Cell death & disease
Yu W,Gowda M,Sharad Y,Singh SA,Sesti F
Published figure using Fyn monoclonal antibody (Product # MA1-19331) in Western Blot
Thu Apr 06 00:00:00 UTC 2017